Sign in

Arshad Hydra

Research Analyst at RBC Capital Markets, LLC

Arshad Hydra is a Research Analyst at RBC Capital Markets specializing in equity research coverage, notably including companies such as XOMA Royalty. His track record reflects direct participation in earnings calls and sector-specific analysis, though publicly available metrics on performance, analyst rankings, or investment returns are currently limited. Hydra's professional background is centered at RBC Capital Markets, with no verified information indicating prior financial institutions in his career history. His professional credentials and securities licenses have not been publicly disclosed.

Arshad Hydra's questions to XOMA Royalty (XOMA) leadership

Question · Q4 2015

Arshad Hydra of RBC Capital Markets questioned the R&D expenditure outlook for 2016 compared to 2015 and asked for details on the number of clinical trial centers for the congenital hyperinsulinism study.

Answer

CFO Tom Burns projected that total 2016 expenses would be approximately 30% lower than in 2015, with a 75% R&D and 25% SG&A split. CEO John Varian and SVP Paul Rubin clarified that while two centers are currently active, XOMA is in discussions with all 10-12 major global centers to expand patient access for future trials.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts